Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 17, 2024Frontiers in Cell and Developmental BiologyOpen Access

Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations

View Full Paper
Ask AI
Bookmark
Share

Authors

BGBeatriz Guijarro-AlbaladejoHospital Universitario Virgen del RocíoCMCristina Marrero-CepedaInstituto de Biomedicina de SevillaEREduardo Rodríguez‐ArbolíInstituto de Biomedicina de Sevilla

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Guijarro-Albaladejo et al. (2024) studied this question.

synapsesocial.com/papers/68e6eabeb6db643587665e1bhttps://doi.org/10.3389/fcell.2024.1376554
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma2022 · 407 citations
  2. 2Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia2014 · 366 citations
  3. 3Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses2012 · 238 citations
  4. 4Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies2022 · 54 citations
  5. 5Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia2022 · 52 citations